<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02617602</url>
  </required_header>
  <id_info>
    <org_study_id>GDT1.0</org_study_id>
    <nct_id>NCT02617602</nct_id>
  </id_info>
  <brief_title>Goal Directed Hemodynamic Management of Acute Heart Failure After Cardiac Surgery in Children</brief_title>
  <official_title>Goal Directed Hemodynamic Management of Acute Heart Failure After Cardiac Surgery in Children: a Prospective Randomised Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Meshalkin Research Institute of Pathology of Circulation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Meshalkin Research Institute of Pathology of Circulation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Goal directed therapy (GDT) utilises various monitoring techniques to assess cardiovascular
      performance and allows for timely interventions based on predetermined algorithms. The aim of
      this prospective randomised study is to evaluate the effect of GDT on major complications in
      children undergoing radical correction of congenital heart defects, complicated by acute
      heart failure. Goal directed therapy will be implemented with the aid of transpulmonary
      thermodilution and based on predetermined algorithms.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2015</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">November 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major complications</measure>
    <time_frame>Through study completion, an average of 30 days</time_frame>
    <description>Composite of all-cause mortality, extracorporal membrane oxygenation use, cardiac arrest, renal impairment (pRIFLE score of &quot;injury&quot; or higher), sepsis</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Cardiac Surgery</condition>
  <arm_group>
    <arm_group_label>Goal directed therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Based on transpulmonary thermodilution, hemodynamic management will be implemented to achieve predefined goals</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Conventional therapy</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Goal directed therapy</intervention_name>
    <description>Based on transpulmonary thermodilution data, the following interventions will be implemented:
Global end diastolic volume (GEDV) ≤ 430 ml/m2 and extravascular water index (EVWI) ≤ 10 ml/kg: fluid load; GEDV ≥ 550 ml/m2 and EVWI ≥ 10 ml/kg: furosemide;
cardiac index (CI) ≤ 2 l/min/m2 - inotropic support:
decreased heart rate (HR): dobutamine, dopamine;
normal or increased HR: epinephrine, norepinephrine; CI ≥ 2 l/min/m2 and normovolemia: phenylephrine.</description>
    <arm_group_label>Goal directed therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Control</intervention_name>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  informed written consent signed by legal representative (parent or guardian)

          -  radical correction of congenital heart defect(s)

          -  use of cardiopulmonary bypass

          -  vasoactive-inotropic Score of 10 or greater during first 24 hours after surgery.

        Exclusion Criteria:

          -  confirmed intranatal infection;

          -  gestational age &lt; 37 weeks;

          -  inotropic support prior to surgery;

          -  acute renal or hepatic failure prior to surgery;

          -  participation in conflicting randomised controlled studies.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Vladimir Lomivorotov, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Novosibirsk Research Institute of Cirulation Pathology</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Vladimir Lomivorotov, PhD</last_name>
    <phone>+79139164103</phone>
    <email>vv_lomivorotov@meshalkin.ru</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dmitry Ponomarev, PhD</last_name>
    <phone>+79232339205</phone>
    <email>d_ponomarev@meshalkin.ru</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Novosibirsk Research Institute of Circulation Pathology</name>
      <address>
        <city>Novosibirsk</city>
        <zip>630055</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dmitry Ponomarev, PhD</last_name>
      <phone>+79232339205</phone>
      <email>d_ponomarev@meshalkin.ru</email>
    </contact>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2015</study_first_submitted>
  <study_first_submitted_qc>November 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 1, 2015</study_first_posted>
  <last_update_submitted>December 17, 2015</last_update_submitted>
  <last_update_submitted_qc>December 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Congenital heart defect</keyword>
  <keyword>Cardiopulmonary bypass</keyword>
  <keyword>Goal directed therapy</keyword>
  <keyword>Acute heart failure</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

